Lingesh Allakonda

Lingesh Allakonda

Auto-generated profile, based on publicly available information

Lingesh Allakonda

Regional Ayurveda Research Institute, Amkhoh, Gwalior, Madhya Pradesh, 474001, India

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
DPDavid Paul
David Paul
LALingesh Allakonda
Lingesh Allakonda
SNSatheesh Kumar Nanjappan
Satheesh Kumar Nanjappan

1 July 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SPSantosh Kumar Prajapti
Santosh Kumar Prajapti
ANAtulya Nagarsenkar
Atulya Nagarsenkar
SGSravanthi Devi Guggilapu
Sravanthi Devi Guggilapu
KGKeshav Kumar Gupta
Keshav Kumar Gupta
LALingesh Allakonda
Lingesh Allakonda
BBBathini Nagendra Babu
Bathini Nagendra Babu

1 February 2017 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
CVChiguru Vishnuvardhan
Chiguru Vishnuvardhan
BSBaikadi Saibaba
Baikadi Saibaba
LALingesh Allakonda
Lingesh Allakonda
DSDebasish Swain
Debasish Swain
SGS. Gananadhamu
S. Gananadhamu
SNSatheesh Kumar Nanjappan
Satheesh Kumar Nanjappan

1 September 2016 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
VCVishnuvardhan Chiguru
Vishnuvardhan Chiguru
ALAllakonda Lingesh
Allakonda Lingesh
SRSrinivas R.
Srinivas R.
SNSatheesh Kumar Nanjappan
Satheesh Kumar Nanjappan

1 January 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
APAjay Godwin Potnuri
Ajay Godwin Potnuri
LALingesh Allakonda
Lingesh Allakonda
AAArulvelan Appavoo
Arulvelan Appavoo
SSSherin Saheera
Sherin Saheera
RNRenuka R. Nair
Renuka R. Nair

1 March 2017 in IJC Metabolic & Endocrine
Verified
Journal Article
Open access
APAjay Godwin Potnuri
Ajay Godwin Potnuri
SKSundar Kumar Kondru
Sundar Kumar Kondru
PSPavan Kumar Samudrala
Pavan Kumar Samudrala
LALingesh Allakonda
Lingesh Allakonda
Back ground: Cardiotoxicity confines the usage of Adriamycin in clinical practice as it can develop cardiac impediments up to 10 years after the termination of therapy. Even though, no specific therapeutic strategies are available for treating adriamycin-induced cardiotoxicity, beta-adrenergic blockers (βB) and angiotensin-converting enzyme (ACE) inhibitors are known to prevent its progression into failure. In this scenario, we attempted to compare the pharmacological outcome of sub-acute βB and ACE inhibitor treatments in preventing adriamycin-induced cardiotoxicity by analysing the differences between them. Methods: Rats received a single bolus dose of adriamycin (10 mg/kg) on day one and treated with either Carvedilol (10 mg/kg) (CAR) or Captopril (50 mg/kg) (CAP) once daily for 28 days. Cardiac morphology, systolic and diastolic functions were evaluated by 2D trans-thoracic echocardiography. Cardiac Troponin and Ck MB levels were measured to analyse the myocyte damage. Myocardial lipid peroxidation, IL1β levels and caspase 3 activity were evaluated as the markers of oxidative stress, inflammation and apoptosis respectively. Results: Both treatments had reduced the adriamycin induced cardiotoxicity. Whereas CAP treatment showed a better reduction of inflammation, superior preservation of posterior wall architecture and enhanced improvement in relative wall thickness when compared to CAR. Oxidative stress, caspase 3 activity and markers of myocyte damage were better recovered with CAR treatment while other parameters were found to be identically attenuated. Conclusion: The present study found an identical therapeutic outcome from ACE inhibition and β blockade with a better attenuation of inflammation and structural preservation with ACE inhibition and superior antioxidant and antiapoptotic effect with βB treatment